DrNose Corporation ★ 0Sign in to vote

Detecting chronic illnesses such as cancer has traditionally relied on invasive and costly methods, but DrNose is introducing an alternative that could make early screening for diagnostics more accessible and affordable.

DrNose has developed an Electronic Nose, a small, portable device that analyses a person’s exhaled breath to detect signs of diseases inexpensively and in real time. The device uses eight highly specialised sensors to identify chemical molecules linked to conditions such as breast and lung cancers, diabetes, and other chronic diseases. Despite its compact design, the device has achieved an accuracy of 90+% in initial clinical trials conducted at institutions such as Ben Gurion University and the University of New South Wales.

This technology is the result of two decades’ worth of research, blending expertise in medicine, electronics, and AI. While animal noses can have millions of receptors—dogs, for instance, have 300 million—the DrNose device uses just eight optimised sensors. These sensors work with proprietary algorithms to deliver precise results.

DrNose’s focus is not just on accuracy but also on accessibility. The device is designed to be affordable and easy to use, making it suitable for rural areas where access to healthcare can be limited. It can also serve as an early health indicator for insurance purposes, helping assess risk quickly and effectively.

DrNose offers a practical and innovative tool to improve health outcomes worldwide.